<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467414</url>
  </required_header>
  <id_info>
    <org_study_id>NN1250-3763</org_study_id>
    <secondary_id>2011-001850-27</secondary_id>
    <secondary_id>U1111-1120-7444</secondary_id>
    <nct_id>NCT01467414</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to investigate the
      pharmacodynamic (the effect of the investigated drug on the body) properties of NN1250
      (insulin degludec) in Japanese subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This trial was terminated due to low recruitment
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the glucose infusion rate curve during one dosing interval at steady state</measure>
    <time_frame>Within 0-24 hours after last dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum glucose infusion rate at steady state</measure>
    <time_frame>Within 0-24 hours after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin degludec concentration-time curve during one dosing interval at steady state</measure>
    <time_frame>Within 0-24 hours after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum insulin degludec concentration at steady state</measure>
    <time_frame>Within 0-24 hours after last dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>NN1250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Injected s.c. (under the skin) once daily for 6 days</description>
    <arm_group_label>NN1250</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Japanese subject aged 20-70 years (both inclusive)

          -  Japanese passport holder

          -  Japanese-born parents

          -  Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months

          -  Treated with insulin for at least 3 months

          -  Body Mass Index (BMI) maximum 33.0 kg/m^2

          -  Glycosylated haemoglobin A1c (HbA1c) maximum 10.0%

          -  Fasting C-peptide below 1.0 nmol/L

        Exclusion Criteria:

          -  Use of oral antidiabetic drugs (OADs) and/or glucagon like peptide-1 (GLP-1) receptor
             agonists (exenatide, liraglutide) within 3 months prior to screening

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Not able or willing to refrain from smoking and use of nicotine gum or transdermal
             nicotine patches during the inpatient period

          -  Supine blood pressure at screening (after resting for 5 min) minimum 180 mmHg for
             systolic and/or minimum 100 mmHg for diastolic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

